Michel Boiron 1925-2018

It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).

Read more

Renew your EHA membership

EHA members will have the chance to renew their membership with the association from today, November 14, 2017.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

Jan Cools Andreas Engert

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

Madrid Declaration: joint call for action on training requirements

madrid decl

The Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive enjoyed broad support from national society representatives at the EHA22 National Societies Dinner in Madrid.

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

eurobloodnet

Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States. At the 3rd conference on European Reference Networks in Lithuania, EuroBloodNet was officially awarded as one of the recently approved ERNs.

Read more

HARMONY: Innovative Medicines Initiative approves € 40 million project for bette...

Logo Harmony Horizontal FullText

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL),...

Read more

HARMONY: Better care of patients with hematologic malignancies kicked off!

Logo Harmony Horizontal FullText

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient...

Read more

EHA’s advocacy for hematology continues

AdobeStock 92093794

EHA is entering the next phase of its Hematology Awareness Campaign this fall. Face-to-face meetings will be conducted with EU institutions and other relevant stakeholders in Brussels, to raise awareness in hematology, increase the visibility of EHA, advocate key EHA positions, contribute to important policy debates and build relationships and alliances.

Read more

Young researchers to benefit from EHA training and mentoring

AdobeStock 135129739

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders i...

lancet

Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

European Reference Networks, a unique opportunity to take collaboration and pati...

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates am...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the...

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more